Viewing stories from July, 2016

28 July 2016
Starpharma initiates new DEP™ drug delivery program with AstraZeneca

Melbourne, Australia; 28 July 2016: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced the initiation a new DEP™ drug delivery program with AstraZeneca. The new agreement will see the application of Starpharma’s DEP™ platform to a further compound from AstraZeneca’s portfolio. 

Read More

21 July 2016
Starpharma signs license for a VivaGel® condom in China

Melbourne, Australia; 21 July 2016: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced the signing of an exclusive license and supply agreement with Shenyang Sky and Land Latex Co. Ltd. (Sky and Land) for the manufacture and sale of VivaGel® condoms to the Government segment of the Chinese condom market. 

Read More

14 July 2016
Appendix 4C - Quarterly Cashflow Report

Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 30 June 2016.

Read More

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.